Replies to post #125 on Trius Therapeutics, Inc. (TSRX)

[ariadndndough]

Public Reply | Private Reply | Keep | Last Read Post New Msg Next 10 | Previous | Next
hptaxis


Tuesday, February 12, 2013 5:21:57 PM
Re: ariadndndough post# 156889

Post # of 156891

Doron S, Boucher HW. Antibiotics for Skin Infections: New Study Design and a Step Toward Shorter Course Therapy. JAMA. 2013;309(6):609-611. http://jama.jamanetwork.com/article.aspx?articleid=1570263

Quote:
Tedizolid is a new oral antibiotic that appears efficacious using a short course and may have a better safety profile than linezolid. The current study brings the Infectious Diseases Society of America's 10 × 20 initiative 1 step closer to its goal of regulatory approval of 10 new antibacterial drugs with activity against drug-resistant bacteria by 2020. If approved, tedizolid will be the first oral drug in this initiative. ESTABLISH-1 also takes an important step toward validating the feasibility of implementing the new FDA end points for ABSSSI. Future studies should add to the understanding of which patients may be treated safely with shorter-course therapy and further explore the correlation between early and sustained response in ABSSSI.